Guided Therapeutics (GTHP) Cash & Equivalents (2010 - 2025)
Guided Therapeutics (GTHP) reported Cash & Equivalents of $63000.0 for Q4 2025, down 83.76% on a YoY basis from $388000.0 in Q4 2024, and down 27.59% sequentially from $87000.0 in Q3 2025.
Guided Therapeutics (GTHP) Cash & Equivalents (2010 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 16 years of Cash & Equivalents data on file, last reported at $63000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents fell 83.76% year-over-year to $63000.0; the trailing twelve-month figure through Dec 2025 stood at $63000.0 (down 83.76% YoY), and the FY2025 full-year result was $63000.0, down 83.76% from the prior year.
- Cash & Equivalents fell to $63000.0 in Q4 2025, from $87000.0 in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $2.7 million in Q3 2022 to a low of $63000.0 in Q4 2025.
- A 5-year average of $790150.0 and a median of $566000.0 in 2021 frame the typical range for Cash & Equivalents.
- Across the five-year window, Cash & Equivalents soared 5838.1% in 2021 and sank 83.76% in 2025, its largest moves.
- Tracing GTHP's Cash & Equivalents over 5 years: stood at $643000.0 in 2021, then jumped by 259.72% to $2.3 million in 2022, then slumped by 74.45% to $591000.0 in 2023, then tumbled by 34.35% to $388000.0 in 2024, then slumped by 83.76% to $63000.0 in 2025.
- Business Quant data shows GTHP's Cash & Equivalents at $63000.0 in Q4 2025, $87000.0 in Q3 2025, and $185000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 6.80 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 2.88 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.95 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.45 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 2.45 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 1.12 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 3.03 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.29 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 557.00 Mn |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | 63,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 63,000.00 |
| Sep 30, 2025 | 87,000.00 |
| Jun 30, 2025 | 185,000.00 |
| Mar 31, 2025 | 115,000.00 |
| Dec 31, 2024 | 388,000.00 |
| Sep 30, 2024 | 194,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Mar 31, 2024 | 445,000.00 |
| Dec 31, 2023 | 591,000.00 |
| Sep 30, 2023 | 731,000.00 |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 1.84 Mn |
| Dec 31, 2022 | 2.31 Mn |
| Sep 30, 2022 | 2.70 Mn |
| Jun 30, 2022 | 446,000.00 |
| Mar 31, 2022 | 725,000.00 |
| Dec 31, 2021 | 643,000.00 |
| Sep 30, 2021 | 541,000.00 |
| Jun 30, 2021 | 922,000.00 |
| Mar 31, 2021 | 1.25 Mn |